Depressive Disorders: A Worrying Landscape

A huge public health issue and a huge, growing market

• Approximately 10% people affected during a lifetime
• Market size (USA+EU): 60 million people

Urgent Needs for a better understanding of the disease and for innovation

• None of the existing treatment meets the complete medical needs:

20% to 40% patients are partial or non responders;
there is a 3-4 week delay before treatments start bringing benefits;
there are systematic, serious side effects (“serotonin syndrom”, mania/hypomania, bleeding, nausea, …);
50% patients discontinue treatment within 6 months because of side effects;
10% patients commit suicide!

• All existing treatments, and all “new” treatments, have the same Mechanism of Action:

they regulate monoamines neurotransmission (SSRIs, SNRIs).

The DEPSTER project, designed and piloted by MAPREG, made the awaited first original proof of concept to relieve depressive situation in relevant animal models.
Now Phase 2 clinical trial is about to be launched.

MAP4343 fills the gaps

A competitive innovative program granted 6th by EUROSTARS

In 3 different animal models of depressive disorder, MP4343*:

• Promotes “coping” ( = suvival ) behaviour
• Decreases Anxiety
• Restores memory and cognitive function
• Restores Sleep efficacy
• Displays an Immediate and persistent activity
• Has no side effect and no sign of drug-abuse
• Activity correlates with rapid changes of tubulin markers, in both brain and plasma ( biomarkers)

*MAP4343 was systematically compared to PROZAC, and proves better in all outcomes.

Aging Brain

Brain inherently ages and becomes slower, subject to failure of memory with correlative loss of self-confidence and desire to act. MAP4343 pharmacological profile allows to propose it as a safe drug to help people fight their cognitive impairments as well as mood disorders.